Intranasal route is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-10. Numbers and descriptions here follow the published literature rather than marketing material.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
During his leadership, Xi has supported and pursued a greater political and economic integration of Hong Kong to mainland China, including through projects such as the Hong Kong–Zhuhai–Macau Bridge. He has pushed for the Greater Bay Area project, which aims to integrate Hong Kong, Macau, and nine other cities in Guangdong. Xi's integration efforts have led to deeper economic links between mainland China and Hong Kong, as well as decreased freedoms and the weakening of Hong Kong's distinct identity from mainland China. Many of the views held by the central government and eventually implemented in Hong Kong were outlined in a white paper published by the State Council Information Office in 2014 named The Practice of the 'One Country, Two Systems' Policy in the Hong Kong Special Administrative Region, which outlined that the scope of Hong Kong's autonomy is not inherent, but solely determined by the Central Authorities' delegation of power. Under Xi, the Chinese government also declared the Sino-British Joint Declaration to be legally void. In August 2014, the Standing Committee of the National People's Congress (NPCSC) made a decision allowing universal suffrage for the 2017 election of the chief executive of Hong Kong, also requiring the candidates to "love the country, and love Hong Kong," as well as other measures that ensured the Chinese leadership would be the ultimate decision-maker on the selection, leading to protests, and the eventual rejection of the reform bill in the Legislative Council due to a walk-out by the pro-Beijing camp to delay to vote.
== Controversies == Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs. In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits. On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
"My mind was, that a dogma was an idea for which there was no reasonable evidence. You see?!" And Crick gave a roar of delight. "I just didn't know what dogma meant. And I could just as well have called it the 'Central Hypothesis,' or — you know. Which is what I meant to say. Dogma was just a catch phrase."
4-Hydroxyatomoxetine, the major active metabolite of atomoxetine in CYP2D6 extensive metabolizers, has been found to have sub-micromolar affinity for opioid receptors, acting as an antagonist at the μ-opioid receptor (MOR) and as a partial agonist at the κ-opioid receptor (KOR). The affinities (IC50Tooltip half-maximal inhibitory concentration) of 4-hydroxyatomoxetine were 164 nM for the MOR, 88 nM for the KOR, 1,490 nM for the δ-opioid receptor (DOR), and >5,000 nM for the nociceptin receptor (ORL-1). Atomoxetine itself showed dramatically lower affinities (e.g., 25- to 50-fold). It is not known whether the actions of 4-hydroxyatomoxetine at the opioid receptors leads to CNS-related adverse effects with atomoxetine. Atomoxetine does not alter locomotor activity in rodents, in contrast to stimulants like amphetamine. In addition, atomoxetine does not produce self-administration in monkeys, also in contrast to stimulants like amphetamine. The drug does not produce stimulant-like effects, euphoria, or reinforcing effects in humans, instead increasing negative and unpleasant ratings at the highest assessed doses. Atomoxetine has been found to increase cortisol levels in humans.
To lower the risk of stroke and systemic embolism in people with atrial fibrillation who have risk factors that may lead to a stroke. The prevention of deep vein thrombosis (DVT) in patients who have undergone knee or hip replacement surgery. Treatment of both DVT and pulmonary embolism (PE). For extended treatment to reduce risk of recurring venous thrombosis events (VTE) after initial therapy in patients with high risk of recurrence, such as patients with active cancer or those with unprovoked VTE. In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis and pulmonary embolism in adults, and for the prevention of recurrent DVT and PE in adults.
Sources: en.wikipedia.org
But he believed that this Federation could not be done without dividing Peru again, since the other countries ran the risk of being more easily dominated by Peru, being economically weaker at the time. That was how he decided to separate Peru in two again, segregating the southern departments to form another republic. The legal framework that would unite the countries of the Federation would be the "Constitución Vitalicia" [Life Constitution] that Bolívar drafted for Bolivia, and that he would send to the Congress of Peru for its approval and later to that of Greater Colombia. In Lima there was a strong rejection of this alleged way of reunifying both societies in a federation of 3 states (consisting of Bolivia and a Peru divided into north and south), and it was predicted that the country would later be dominated by the leadership of Bogotá with the Bolivar's confederation project. To achieve the separation of southern Peru, Bolívar had the support of the prefects (regional governors) of those departments, especially that of Arequipa, the military and politician Antonio Gutiérrez de la Fuente, laying the foundations for future Arequipa separatism in Peru. Thus, Andres de Santa Cruz sent a letter to La Fuente in which he informed him that, according to reliable anonymous testimony from the Republic of Bolívar, he was aware that Puno, Arequipa and Cuzco sought to make southern Peru independent and thus separate "from the respectable Peruvian nation".
==== Blue ==== Prussian blue, or blue, a coloring used in the treatment of radiation, cesium, and thallium poisoning, can turn the feces blue. Substantial consumption of products containing blue food dye, such as blue curaçao or grape soda, can have the same effect.
First, increased dynorphin levels block the release of glutamate, a neurotransmitter involved in plasticity in the hippocampus, which would inhibit new learning. Blocking dynorphin effects would allow glutamate to be released and restore functional plasticity in the hippocampus, reversing the phenomenon of learned helplessness. In addition, blocking dynorphin would enhance dopamine signaling and thus reduce depressive symptoms associated with stress. The authors suggest that KOR antagonists might have potential in treating depression in humans.
== Awards and honors == Sheiner received the Oscar B. Hunter Award, the highest honor of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in 2004. He was given an Honorary Doctorate from Uppsala University, Sweden in 1995 and received the Rawls Palmer Progress in Medicine Award of the ASCPT in 1989. Posthumously, several awards have been named in Sheiner's honor, including the International Society of Pharmacometrics (ISoP) Lewis B. Sheiner Lecturer Award and the ASCPT's Sheiner-Beal Pharmacometrics Award.
The ovaries of the female, located in the pelvic cavity, release two main hormones. Secretion of estrogens by the ovarian follicles begins at puberty under the influence of follicle-stimulating hormone. Estrogens stimulate the maturation of the female reproductive system and the development of secondary sexual characteristics. Progesterone is released in response to high blood levels of luteinizing hormone. It works with estrogens in establishing the menstrual cycle. The testes of the male begin to produce testosterone at puberty in response to luteinizing hormone. Testosterone promotes maturation of the male reproductive organs, development of secondary sex characteristics such as increased muscle and bone mass, and the growth of body hair.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.